Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Significant default risk
Profitability factor
Favourable analyst view
Very low or no dividends
Very poor margins and returns
Risk / Profitability
Risk: High
Profitability: Average
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Significant default risk
Profitability factor
Favourable analyst view
Very low or no dividends
Very poor margins and returns
$ 13.34
About
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered...
About
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.